283 related articles for article (PubMed ID: 23296196)
1. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis.
Cremin I; Alsallaq R; Dybul M; Piot P; Garnett G; Hallett TB
AIDS; 2013 Jan; 27(3):447-58. PubMed ID: 23296196
[TBL] [Abstract][Full Text] [Related]
2. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study.
Hallett TB; Baeten JM; Heffron R; Barnabas R; de Bruyn G; Cremin Í; Delany S; Garnett GP; Gray G; Johnson L; McIntyre J; Rees H; Celum C
PLoS Med; 2011 Nov; 8(11):e1001123. PubMed ID: 22110407
[TBL] [Abstract][Full Text] [Related]
3. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
Long EF; Stavert RR
J Gen Intern Med; 2013 Oct; 28(10):1294-301. PubMed ID: 23588668
[TBL] [Abstract][Full Text] [Related]
4. Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?
Verguet S; Stalcup M; Walsh JA
Sex Transm Infect; 2013 Dec; 89(8):628-34. PubMed ID: 23912819
[TBL] [Abstract][Full Text] [Related]
5. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL
J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936
[TBL] [Abstract][Full Text] [Related]
6. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
[TBL] [Abstract][Full Text] [Related]
7. Combined interventions to reduce HIV incidence in KwaZulu-Natal: a modelling study.
Blaizot S; Huerga H; Riche B; Ellman T; Shroufi A; Etard JF; Ecochard R
BMC Infect Dis; 2017 Jul; 17(1):522. PubMed ID: 28747167
[TBL] [Abstract][Full Text] [Related]
8. The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study.
Gomez GB; Borquez A; Caceres CF; Segura ER; Grant RM; Garnett GP; Hallett TB
PLoS Med; 2012; 9(10):e1001323. PubMed ID: 23055836
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.
Alistar SS; Grant PM; Bendavid E
BMC Med; 2014 Mar; 12():46. PubMed ID: 24629217
[TBL] [Abstract][Full Text] [Related]
10. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries.
Pretorius C; Schnure M; Dent J; Glaubius R; Mahiane G; Hamilton M; Reidy M; Matse S; Njeuhmeli E; Castor D; Kripke K
J Int AIDS Soc; 2020 Feb; 23(2):e25451. PubMed ID: 32112512
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and cost-effectiveness of early antiretroviral therapy and partners' pre-exposure prophylaxis among men who have sex with men in Shenyang, China: a prospective cohort and costing study.
Hu QH; Meyers K; Xu JJ; Chu ZX; Zhang J; Ding HB; Han XX; Jiang YJ; Geng WQ; Shang H
BMC Infect Dis; 2019 Jul; 19(1):663. PubMed ID: 31345169
[TBL] [Abstract][Full Text] [Related]
12. A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.
Li J; Peng L; Gilmour S; Gu J; Ruan Y; Zou H; Hao C; Hao Y; Lau JT
BMC Infect Dis; 2018 Nov; 18(1):600. PubMed ID: 30486800
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa.
Pretorius C; Stover J; Bollinger L; Bacaër N; Williams B
PLoS One; 2010 Nov; 5(11):e13646. PubMed ID: 21079767
[TBL] [Abstract][Full Text] [Related]
14. Economics of antiretroviral treatment vs. circumcision for HIV prevention.
Bärnighausen T; Bloom DE; Humair S
Proc Natl Acad Sci U S A; 2012 Dec; 109(52):21271-6. PubMed ID: 23223563
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa.
Abbas UL; Glaubius R; Mubayi A; Hood G; Mellors JW
J Infect Dis; 2013 Jul; 208(2):224-34. PubMed ID: 23570850
[TBL] [Abstract][Full Text] [Related]
16. Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria.
Mitchell KM; Lépine A; Terris-Prestholt F; Torpey K; Khamofu H; Folayan MO; Musa J; Anenih J; Sagay AS; Alhassan E; Idoko J; Vickerman P
AIDS; 2015 Sep; 29(15):2035-44. PubMed ID: 26355574
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
[TBL] [Abstract][Full Text] [Related]
18. The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study.
Bórquez A; Guanira JV; Revill P; Caballero P; Silva-Santisteban A; Kelly S; Salazar X; Bracamonte P; Minaya P; Hallett TB; Cáceres CF
Lancet Public Health; 2019 Mar; 4(3):e127-e136. PubMed ID: 30683587
[TBL] [Abstract][Full Text] [Related]
19. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.
Drabo EF; Hay JW; Vardavas R; Wagner ZR; Sood N
Clin Infect Dis; 2016 Dec; 63(11):1495-1504. PubMed ID: 27558571
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.
Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL
Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]